Abstract:Abstract Background Therapeutic drug monitoring (TDM) of vancomycin is widely recommended for clinical treatment. Due to the complexity of 24-h area under the curve (AUC) guided vancomycin monitoring in clinical practice, the vancomycin trough level remains the most common and practical method. The purpose of this study was designed to investigate the differences in the safety and efficacies of vancomycin TDM based on the two different monitoring methods, and further explore the clinical application of trough-guided vancomycin monitoring in patients with gastrointestinal cancer requiring mechanical ventilation. Methods We included a total of 78 gastrointestinal cancer patients who required mechanical ventilation due to various diseases. All patients included in this study were aged 18 years or older and were treated with intravenous vancomycin therapy for more than 2 days due to documented or suspected Gram-positive bacterial infections, and have at least one available vancomycin plasma concentration. First, we compared the safety and efficacies of vancomycin TDM based on different monitoring methods as trough-guided monitoring or AUC-guided monitoring. Then, based on whether the initial vancomycin concentration achieving the target trough concentration (less than 48 h), patients were divided into early and delayed groups, and the clinical factors were compared between them. The primary endpoints include the incidence of new-onset acute kidney injury (AKI) or renal replacement therapy (RRT), clinical success rate and 28-day all-cause mortality. Finally, the overall relationship between trough concentration and potential covariates is screened by univariate and multivariate analysis to explore potential information covariates. Results The research revealed that patients with gastrointestinal cancer exhibited significantly lower initial vancomycin trough concentrations (median [interquartile range (IQR)]: 6.90[5.28-11.20] mg/L). And there were no statistically significant differences in the safety and efficacies of vancomycin TDM based on the two different monitoring methods for the primary endpoint. Moreover, base on trough-guided vancomycin monitoring, the early group demonstrated a notably shorter duration of mechanical ventilation compared with the delayed group (χ 2 = 4.532; p < 0.05; Fig. 2E). Propensity score weighting further confirmed that the duration of mechanical ventilation (χ 2 = 6.607; p < 0.05; Fig. 2F) and duration of vasoactive agent (χ 2 = 6.106; p < 0.05; Fig. 2D) were significantly shorter in the early group compared with delayed group. Multivariate regression analysis revealed that Cystatin C (Cys-C) was the most important variable for vancomycin target trough achievement (odds ratio, 5.274; 95% CI, 1.780 to 15.627; p = 0.003). Conclusions Trough-guided vancomycin monitoring is a simple and effective marker of TDM for ventilated patients with gastrointestinal cancer. Timely achievement of target trough concentrations for vancomycin can improve partial clinical outcomes in Gram-positive bacterial infections. Cys-C level is a potentially valuable parameter for predicting the vancomycin concentration.

Analysis of Vancomycin Concentrations on Critical Patients with High Cre-atinine Clearance Rate

Simulation of Vancomycin Exposure Using Trough and Peak Levels Achieves the Target Area under the Steady-State Concentration-Time Curve in ICU Patients

Analysis the relationship between vancomycin serum concentration and nephrotoxicity or clinical efficiency

Application of therapeutic drug monitoring of vancomycin

A Higher Dose of Vancomycin is Needed in Critically Ill Patients with Augmented Renal Clearance

Target Serum Concentration of Vancomycin May Be Reached Earlier with a Loading Dose

Clinical application of vancomycin TDM in ventilated patients with gastrointestinal cancer: a propensity-matched analysis

[Monitoring of Vancomycin Serum Concentrations and the Evaluation of Its Safety and Treatment Outcomes in Adult Patients].

[Study on the Optimization of Administration Regimen of Vancomycin in Critical Patients].

Factors influencing vancomycin trough concentration in burn patients: a single center retrospective study

Determination of vancomycin exposure target and individualized dosing recommendations for critically ill patients undergoing continuous renal replacement therapy

Serum vancomycin levels in critically ill elderly patients undergoing continuous renal replacement therapy

No one-size-fits-all approach: Retrospective analysis of efficacy and safety of serum concentrations of continuously administered vancomycin in critically ill adults reveals different target serum concentrations depending on disease severity

Earlier Targeted Vancomycin Troughs Concentration with Loading Dose: A Retrospective Study

An Evaluation on the Association of Vancomycin Trough Concentration with Mortality in Critically Ill Patients: A Multicenter Retrospective Study

Relationship Between Mean Vancomycin Trough Concentration and Mortality in Critically Ill Patients: A Multicenter Retrospective Study

Analysis of drug concentration monitoring on serum and clinical rational use of vancomycin

Clinical analysis of vancomycin usage in intensive care unit

Analysis on therapeutic drug monitoring data of vancomycin in 64 elderly patients

Clinical Efficacy and Nephrotoxicity of High or Low Vancomycin Trough Concentration Therapy

The Effect of Renal Clearance on Serum Trough Concentration of Vancomycin in Elderly Patients with Severe Pneumonia